Normal function · from ai-gene-review (Q9C0B1, commit 79fe13b38970) · AI-generated, not KB evidence

Nuclear, Fe(II)- and 2-oxoglutarate-dependent oxygenase of the AlkB superfamily that oxidizes methyl groups on single-stranded nucleic acids. Its AlkB-like catalytic domain is paired with a C-terminal domain of novel fold, and an active-site loop excludes duplex substrates, so FTO acts only on single-stranded DNA and RNA. The best-supported cellular substrates are methylated adenosines in small RNAs and mRNA: N6,2'-O-dimethyladenosine (m6Am) at the transcription-start nucleotide of snRNAs and of capped mRNAs, N6-methyladenosine in U6 snRNA, and N1-methyladenosine in tRNA, the last of which represses translation. FTO can also oxidize internal N6-methyladenosine in mRNA and, in vitro, repair-type lesions such as 3-methylthymine in ssDNA and 3-methyluracil in ssRNA. Two aspects of its activity are actively disputed. Chemically, isolated FTO appears to stop at the hemiaminal N6-hydroxymethyladenosine rather than releasing formaldehyde itself, so demethylation may complete non-enzymatically, unlike the related ALKBH5 and AlkB enzymes. Biologically, whether internal mRNA m6A is a physiological substrate is contested: antibody-based transcriptome mapping supports it, while quantitative direct-RNA sequencing finds no change in mRNA m6A stoichiometry on FTO loss, with snRNA m6Am rising instead. FTO is mainly nuclear, concentrating in nuclear speckles, with a cell-type-dependent cytoplasmic pool. Complete loss of catalytic activity causes a lethal recessive polymalformation syndrome in humans, and the protein is widely studied as a candidate target in acute myeloid leukemia. Common variants in FTO intron 1 give the strongest known common-variant association with body mass index, but that association acts largely by altering enhancer-driven expression of the distant IRX3 and IRX5 genes rather than by altering FTO protein function.

Fe(II)- and 2-oxoglutarate-dependent oxidative removal of methyl groups from adenosine residues in single-stranded RNA. The best-established cellular substrates are N6,2'-O-dimethyladenosine (m6Am) at the transcription-start nucleotide of snRNAs and of capped mRNAs, and N6-methyladenosine in U6 snRNA; FTO also oxidizes internal m6A in mRNA in vitro, though whether mRNA m6A is a physiological substrate is disputed. An active-site loop restricts FTO to single-stranded substrates. Recent chemistry indicates the isolated enzyme stops at the hemiaminal N6-hydroxymethyladenosine, with release of formaldehyde occurring by slow non-enzymatic fragmentation, so the demethylated product may form off-enzyme.
Removal of N1-methyladenosine from tRNA. FTO acts on both nuclear and cytoplasmic tRNA pools; loss of FTO raises tRNA m1A in human knockdown cells and in Fto-knockout mouse cells, and the effect size is substantially larger than the changes seen for m6A or cap m6Am in polyadenylated RNA. Demethylation of tRNA m1A by FTO directly represses translation, making this the FTO activity with the clearest cellular consequence.
The catalytic identity of FTO, and the one molecular-function statement untouched by either current dispute. FTO couples oxidation of a methyl group on a single-stranded nucleic acid to decarboxylation of 2-oxoglutarate at a mononuclear Fe(II) centre, releasing succinate and CO2. This holds whether the enzymatic product is the demethylated base or the hemiaminal, and whatever the physiological substrate turns out to be. Homozygous loss of this activity in humans (R316Q) causes a lethal polymalformation syndrome.
molecular function: 2-oxoglutarate-dependent dioxygenase activity · directly involved in: oxidative RNA demethylation · locations: nucleus
In the knowledge base · computed from kb/ at build time

Disorders

Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.

DisorderRelationshipWhere the gene appears
Obesity risk factor germline
Hospital-Acquired Acute Kidney Injury untyped
Associated
Lethal Polymalformative Syndrome, Boissel Type untyped
Biallelic missense, loss of demethylase function
germline loss of function
mechanism: Biallelic FTO missense variant
variant: FTO c.287G>C p.Arg96Pro; FTO c.812A>C p.His271Pro; FTO c.947G>A p.Arg316Gln; FTO c.956C>T p.Ser319Phe; FTO c.965G>A p.Arg322Gln
Microcephaly, Short Stature, and Impaired Glucose Metabolism 1 no genetic record
mechanism: Coordinated mRNA m6A Dysregulation via the FTO Axis

Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.